Reauthorization of the Prescription Drug User Fee Act; Public Meeting; Request for Comments
What happened
The Food and Drug Administration (FDA) is hosting a public meeting to discuss proposed recommendations for reauthorizing the Prescription Drug User Fee Act (PDUFA) for fiscal years (FYs) 2028 through 2032. This act allows the FDA to collect user fees to support the process for reviewing human drug applications. Current legislative authority for PDUFA expires in September 2027, requiring new legislation to continue fee collection.
Why it matters
This reauthorization process ensures the FDA can continue funding its review of new prescription drugs, which impacts their availability. Public input helps shape the final recommendations for this important regulatory function.
Who it affects
- ›The Food and Drug Administration (FDA)
- ›Regulated industry (drug manufacturers)
- ›Public stakeholders
- ›Patients needing human drug applications
The receipts are official. The summary is ours.
Read on Federal Register ↗Summaries are generated from the official text and may simplify or omit nuance. The official document is the source of truth.